Literature DB >> 16969512

Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation.

J Haveman1, J Sigmond, C van Bree, N A Franken, C Koedooder, G J Peters.   

Abstract

Single high dose rate irradiation of 4 Gy in SW-1573 cells, derived from non-small cell lung cancer, led to increased activities of deoxycytidine kinase (dCK) and thymidine kinase 1 and 2 (TK1 and 2). The activity of dCK increased by approximately 30% between 1 and 5 h after irradiation, after which the activity returned to the level of control cells by 8 h after irradiation. TK1 activity also increased by 30-50% between 1 and 6 h after irradiation. The decline to normal levels of dCK concurred with a further increase in the activity of TK1, 8 h after irradiation. TK2 activity was below control levels during the first 4 h after irradiation but rose 3-fold at 8 and 16 h after treatment. The activities of TK1 and TK2 had returned to approximate control levels 24 h after irradiation. The observation that mitochondrial TK2 activity increased to a very high level after irradiation may indicate that the activity of this enzyme is not only important for the damage to mitochondrial DNA, the increased activity may also be instrumental for repair of damage to nuclear DNA. We presume that the increase in activity of TK1 after irradiation is limited to cells in S-phase. Recruitment of cells into S-phase, to replace cells killed by irradiation, is probably too slow to offer an explanation for the enhanced activity of TK1 8 h after irradiation. The increase in activity of both dCK, and TK1 and 2 might be involved in an adaptive response of the cells to radiation by facilitation of DNA repair. The expression of protein kinase C (PKC) decreased during the first 5 h after irradiation. At 5 h after irradiation the level of expression had decreased by >50%. The decrease in PKC expression is concurrent with the increase in dCK activity. This suggests a role of PKC in the signal transduction from DNA damage to the increase in activity of enzymes instrumental in DNA repair.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969512     DOI: 10.3892/or.16.4.901

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

2.  Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.

Authors:  Yusuf Menda; Laura L Boles Ponto; Kenneth J Dornfeld; Timothy J Tewson; G Leonard Watkins; Michael K Schultz; John J Sunderland; Michael M Graham; John M Buatti
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

3.  FISH comets show that the salvage enzyme TK1 contributes to gene-specific DNA repair.

Authors:  Katherine A McAllister; Akeel A Yasseen; George McKerr; C S Downes; Valerie J McKelvey-Martin
Journal:  Front Genet       Date:  2014-08-08       Impact factor: 4.599

4.  The Role of Deoxycytidine Kinase (dCK) in Radiation-Induced Cell Death.

Authors:  Rui Zhong; Rui Xin; Zongyan Chen; Nan Liang; Yang Liu; Shumei Ma; Xiaodong Liu
Journal:  Int J Mol Sci       Date:  2016-11-21       Impact factor: 5.923

5.  Methylation status of TK1 correlated with immune infiltrates in prostate cancer.

Authors:  Chenming Zhang; Sicheng Ma; Xiaohui Hao; Zulong Wang; Zixue Sun
Journal:  Front Genet       Date:  2022-08-11       Impact factor: 4.772

6.  Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance.

Authors:  Yuri L Bunimovich; Evan Nair-Gill; Mireille Riedinger; Melissa N McCracken; Donghui Cheng; Jami McLaughlin; Caius G Radu; Owen N Witte
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.